ACCESS HYBRITECH P2PSA ON THE ACCESS IMMUNOASSAY SYSTEMS

P2psa

FDA Premarket Approval P090026

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the access hybritech p2psa on the access immunoassay systems. This device is indicated for: the access hybritech p2psa assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of [-2]propsa antigen, an isoform of freepsa, in human serum using the access immunoassay systems. Access hybritech p2psa is intended to be used in combination with access hybritech (total) psa and access hybritech free psa to calculate the beckman coulter prostate health index (phi), an in vitro diagnostic multivariate index assay (ivdmia). Beckman coulter phi as calculated using the access hybritech assays is indicated for use asan aid in distinguishing prostate cancer from benign prostatic conditions, for prostate cancer detection in men aged 50 years and older with total psa >= 4. 0 to

DeviceACCESS HYBRITECH P2PSA ON THE ACCESS IMMUNOASSAY SYSTEMS
Classification NameP2psa
Generic NameP2psa
ApplicantBECKMAN COULTER, INC.
Date Received2009-11-17
Decision Date2012-06-14
Notice Date2012-06-20
PMAP090026
SupplementS
Product CodeOYA
Docket Number12M-0638
Advisory CommitteeImmunology
Expedited ReviewNo
Combination Product No
Applicant Address BECKMAN COULTER, INC. 1000 Lake Hazeltine Dr. chaska, MN 55318
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P090026Original Filing
S031 2021-04-19 Real-time Process
S030 2020-09-30 Real-time Process
S029 2020-07-22 Real-time Process
S028 2020-06-23 Real-time Process
S027 2019-12-18 Real-time Process
S026 2019-05-13 Real-time Process
S025 2019-05-02 Real-time Process
S024
S023 2018-12-17 30-day Notice
S022 2018-09-25 Real-time Process
S021 2017-09-28 30-day Notice
S020
S019 2017-06-09 30-day Notice
S018 2017-03-22 Real-time Process
S017 2017-01-23 30-day Notice
S016 2017-01-17 30-day Notice
S015 2015-05-07 Real-time Process
S014 2014-11-04 135 Review Track For 30-day Notice
S013 2014-08-25 Real-time Process
S012 2014-08-25 135 Review Track For 30-day Notice
S011 2014-06-12 30-day Notice
S010 2013-12-17 Real-time Process
S009 2013-09-26 Special (immediate Track)
S008 2013-06-13 Special (immediate Track)
S007 2013-04-12 Special (immediate Track)
S006 2013-03-29 Real-time Process
S005 2013-01-23 Real-time Process
S004 2013-01-03 30-day Notice
S003
S002
S001 2012-10-25 Special (immediate Track)

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.